Literature DB >> 18006909

Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: a tale of two choices--counterpoint.

Carol Fabian1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18006909     DOI： 10.1158/1055-9965.EPI-06-1065

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN： 1055-9965            Impact factor:   4.254


× No keyword cloud information.
  5 in total

1.  hPMC2 is required for recruiting an ERbeta coactivator complex to mediate transcriptional upregulation of NQO1 and protection against oxidative DNA damage by tamoxifen.

Authors:  S P Sripathy; L J Chaplin; N W Gaikwad; E G Rogan; M M Montano
Journal:  Oncogene       Date:  2008-07-28       Impact factor: 9.867

2.  Metabolic Syndrome and Breast Cancer Risk: Is There a Role for Metformin?

Authors:  Catherine Ibarra-Drendall; Eric C Dietze; Victoria L Seewaldt
Journal:  Curr Breast Cancer Rep       Date:  2011-07-13

3.  Metformin- A Promising Agent for Chemoprevention in BRCA1 Carriers.

Authors:  Nagi B Kumar; Susan T Vadaparampil; Nupam Mahajan; Howard S Lilienfeld; Ji-Hyun Lee; Christine Laronga; Ardeshir Hakam; John J Hein; Kathleen M Egan; Banu Arun; Tuya Pal
Journal:  Hereditary Genet       Date:  2012-06

Review 4.  Drug Repurposing Approaches to Combating Viral Infections.

Authors:  Jay Trivedi; Mahesh Mohan; Siddappa N Byrareddy
Journal:  J Clin Med       Date:  2020-11-23       Impact factor: 4.241

Review 5.  Mitochondrial and nuclear genomics and the emergence of personalized medicine.

Authors:  Ryan L Parr; Luis H Martin
Journal:  Hum Genomics       Date:  2012-07-05       Impact factor: 4.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.